Wei Geng, Fansheng Kong, Huanhuan Gao, Hongjin Chang, Jiahui Wang, Na Zhang, Dongqing Han, Yan Zhao. The HLA Epitope Donor Database for Platelet Matching[J]. Blood&Genomics, 2024, 8(1): 10003. DOI: 10.70322/BG20240110003
Citation: Wei Geng, Fansheng Kong, Huanhuan Gao, Hongjin Chang, Jiahui Wang, Na Zhang, Dongqing Han, Yan Zhao. The HLA Epitope Donor Database for Platelet Matching[J]. Blood&Genomics, 2024, 8(1): 10003. DOI: 10.70322/BG20240110003

The HLA Epitope Donor Database for Platelet Matching

Funds: 

This work was supported by the Projects of Medical and Health Technology Development Program in Shandong (No. 202102070720).

More Information
  • Received Date: 2024-03-11
  • Accepted Date: 2024-06-29
  • Available Online: 2024-06-27
  • Published Date: 2025-06-21
  • This study aims to create a platelet donor database with detailed HLA epitope typing in the Jining area and to serve as a solid foundation for treating refractory thrombocytopenia patients who require platelet transfusions. HLA-A, -B epitope phenotype data were collected from a total of 565 unrelated healthy populations in the Jining area. According to the data, a platelet donor database was created and established with known HLA epitope phenotypes. The database donors' HLA-A, -B epitopes were tested separately by sequence-specific primer (PCR-SSP). According to the distribution frequency of HLA-A, -B epitope phenotypes (n = 565), the following results were obtained: 73 HLA-A, -B phenotypes, including 55 with a frequency > 0.003. The sum of frequencies was 96.81%. With a database size of 565 donors, an approximate 84.20% patient HLA-A, -B cross-reactive group (CREG) match coverage was achieved. When it was necessary for identical ABO-type platelet transfusion, the corresponding database modifications were made according to the distribution frequency of the ABO blood group of the population.This study provides the concept for a platelet epitope matching database. It establishes a donor database of known platelet HLA epitopes in the Jining population, which lays a solid foundation for the safe treatment of platelet transfusion in this area.
  • [1]
    . Wu G, Zhou Y, Li L, Zhong Z, Li H, Li H, et al. Platelet Immunology in China: Research and Clinical Applications. Transfus. Med. Rev. 2017, 31, 118–125.
    [2]
    . Chen XW, Yu XF, Tian ZS. Transfusion Therapeutics; Science Press: Beijing, China, 2012; pp. 134–141.
    [3]
    . Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, et al. Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 2001, 19, 1519–1538.
    [4]
    . Brown CJ, Navarrete CV. Clinical relevance of the HLA system in blood transfusion. Vox Sang. 2011, 101, 93–105.
    [5]
    . Petz LD, Garratty G, Calhoun L, Clark BD, Terasaki PI, Gresens C, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000, 40, 1446–1456.
    [6]
    . Brand A, van Leeuwen A, Eernisse JG, van Rood JJ. Platelet transfusion therapy. Optimal donor selection with a combination of lymphocytotoxicity and platelet fluorescence tests. Blood 1978, 51, 781–788.
    [7]
    . Stanworth SJ, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness–practical approaches and ongoing dilemmas in patient management. Br. J. Haematol. 2015, 171, 297–305.
    [8]
    . Zhao TM, Hong JL, Liu JH, Gao DY, Liu Q, Du D, et al. Probability of finding HLA-matched unrelated marrow donor from Chinese Marrow Donor Program. Chin. J. Blood Transfus. 2013, 26, 506–510.
    [9]
    . Vassallo RR. Changing paradigms in matched platelet support. Transfusion 2008, 48, 204–206.
    [10]
    . Duquesnoy RJ. Structural epitope matching for HLA-alloimmunized thrombocytopenic patients: A new strategy to provide more ef fective platelet transfusion support? Transfusion. 2008, 48, 221–227.
    [11]
    . Duquesnoy RJ, Marrari M. HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. II. Verification of the algorithm and determination of the relative immunogenicity of amino acid triplet-defined epitopes. Hum. Immunol. 2002, 63, 353–363.
    [12]
    . Duquesnoy RJ, Howe J, Takemoto S. HLAmatchmaker: A molecularly based algo rithm for histocompatibility determination. IV. An alternative strategy to increase the number of compatible donors for highly sensitized patients. Transplantation 2003, 75, 889–897.
    [13]
    . Tambur AR, Claas FH. HLA epitopes as viewed by antibodies: What is it all about? Am. J. Transplant. 2015, 15, 1148–1154.
    [14]
    . Kallon D, Navarrete CV, Sage DA, Stanworth S, Mufti GJ, Marsh JCW, et al. Impact of Human Leucocyte Antigen epitope matched platelet transfusions in alloimmunised aplastic anaemia patients. Transfus. Med. 2020, 30, 23–29.
    [15]
    . Marsh JC, Stanworth SJ, Pankhurst LA, Kallon D, Gilbertson AZ, Pigden C, et al. An epitope-based approach of HLA-matched platelets for transfusion: A noninferiority crossover randomized trial. Blood 2021, 137, 310–322.
    [16]
    . Tambur AR. HLA-Epitope Matching or Eplet Risk Stratification: The Devil Is in the Details. Front. Immunol. 2018, 9, 2010.
    [17]
    . Lemieux W, Mohammadhassanzadeh H, Klement W, Daniel C, Sapir-Pichhadze R. Matchmaker, matchmaker make me a match: Opportunities and challenges in optimizing compatibility of HLA eplets in transplantation. Int. J. Immunogenet. 2021, 48, 135–144.
    [18]
    . Zhao TM. The formula for estimating the probability of finding HLA-Matched unrelated marrow donor and its application. Chin. J. Blood Transfus. 2003, 16, 381–384.
    [19]
    . Yu M, Li LL, Li HC, Lu F, Pei YF, Huang HN, et al. The design and establishment of the platelet donor database with known HLA/HPA genotype in Nanning area. Chin. J. Blood Transfus. 2018, 31, 1265–1270.
    [20]
    . Excoffier L, Lischer HE. Arlequin suite ver 3.5: A new series of programs to perform population genetics analyses under Linux and Windows. Mol. Ecol. Resour. 2010, 10, 564–567.
    [21]
    . Forest SK, Hod EA. Management of the Platelet Refractory Patient. Hematol Oncol Clin North Am. 2016, 30, 665–667.
    [22]
    . Wu GG, Shen WD. Reflections on the construction of platelet immunology in China. Chin. J. Blood Transfus. 2014, 27, 5–7.
    [23]
    . Wu GG. Detection of clinically relevant platelet antibodies in the Asian population. ISBT Sci. Ser. 2014, 9, 112–117.
    [24]
    . Qi J, Li YH, Wang TJ, Li FQ, Wu JH, Shang LX, et al. The capacity evaluation and utilization strategy of the platelet donor database with known HLA/HPA genotype in Shaanxi. Chin. J. Blood Transfus. 2022, 35, 799–804.
  • Related Articles

    [1]Fansheng Kong, Hongjun Gao, Wei Geng. The CREG Public Epitope Donor Database May Serve as a Convenient Method for Rapidly Identifying HLA-Matched Platelet Donors[J]. Blood&Genomics, 2024, 8(1): 10009. DOI: 10.70322/BG20240110009
    [2]Dongmei Li, Dongjing Liu, Yi Zha, Tao Wu, Yan Qiu. The polymorphisms of HLA class Ⅰ and Ⅱalleles were not associated with severe acute respiratory syndrome among recovered patients in Beijing: a case-control study[J]. Blood&Genomics, 2019, 3(1): 19-25. DOI: 10.46701/APJBG.2019012018140
    [3]Xiangyan Huang. Management and cause analysis of platelet transfusion refractoriness[J]. Blood&Genomics, 2018, 2(4): 217-222. DOI: 10.46701/APJBG.2018042018134
    [4]Guadalupe E. Estrada-Chávez, Roberto Estrada, Guadalupe Chavez, María-Elisa Vega Memije, Roberto Arenas Guzmán, Maricela García-Lechuga, Julio Granados, Lucia Rangel-Gamboa. HLA class Ⅱ alleles in human sporotrichosis in Mexican Amerindians[J]. Blood&Genomics, 2018, 2(3): 183-190. DOI: 10.46701/APJBG.2018032018119
    [5]Tiejun Song, Jun Huang, Ying Zhang, Yingjian Wang, Yetao Han, Mengsi Hu, Zhiwei Liu. One case of platelet donor selection for a platelet transfusion refractory patient of the ethnic minority descent[J]. Blood&Genomics, 2018, 2(2): 129-131. DOI: 10.46701/APJBG.2018022018114
    [6]Dongjing Liu, Yan Qiu, Yi Zha, Wei Li, Dongmei Li, Tao Wu. Association of HLA classⅠand classⅡgenes with severe acute respiratory syndrome in the northern Chinese population[J]. Blood&Genomics, 2018, 2(2): 91-96. DOI: 10.46701/APJBG.2018022018101
    [7]Yanjun Jia, Wei Li, Lijun Wang, Na Liu, Dongmei Wang, Dongmei Li, Yuanyuan Jing, Jie Wang, Zhongmei Wang, Xiaoyan Shan. Allele and haplotype frequencies of human leukocyte antigen-A, -B, -C,-DRB1, and -DQB1 in Chinese patients with hematological diseases[J]. Blood&Genomics, 2018, 2(1): 27-37. DOI: 10.46701/APJBG.2018012017064
    [8]Haochun Chang, Hsin-Wan Chen, Chen Cao, Xiaojie Zhu, Zhenzhen Zhou, Yu-Shiang Lin. Polymorphism of SLC14A1 encoding human erythrocytic Kidd antigens in the Chinese population[J]. Blood&Genomics, 2017, 1(4): 43-46. DOI: 10.46701/APJBG.2017042017056
    [9]Pu Xu, Yan Li, Su Zhou, Ziqi He, You Yang, Hua Yu. Human RBC alloimmunization evaluation after exposure to foreign E antigen of the rhesus system in transfusion[J]. Blood&Genomics, 2017, 1(1): 37-42. DOI: 10.46701/APJBG.20170116009
    [10]Meng Gao, Rong Huang, Hao Tang, Yunfeng Fu, Fengxia Liu, Rong Gui. A Chinese perspective on factors and molecular mechanisms that influence the curative effects of platelet transfusion[J]. Blood&Genomics, 2017, 1(1): 11-16. DOI: 10.46701/APJBG.20170116014

Catalog

    Article Metrics

    Article views (89) PDF downloads (12) Cited by()
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return